Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioLance
- Development stage
- Unknown
- Lead developer
- Takgene
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
BioLance is a probiotic-based oral rehydration therapy developed and marketed by Takgene. It is formulated as a sachet containing the probiotic bacterium *Lactobacillus reuteri*, zinc gluconate, vitamin A, and oral rehydration salts (ORS) consisting of potassium chloride, sodium citrate, sodium chloride, and glucose. BioLance is indicated for the treatment of acute and persistent diarrhea, as well as mild to moderate dehydration in children. The combination of *Lactobacillus reuteri* with zinc, vitamin A, and ORS helps shorten the duration and severity of diarrheal episodes, restore intestinal microflora balance, and modulate immune responses.
- Brand names
- BioLance
- Other names
- Biolancبایولانس
Beyond the preview
Go deeper on BioLance.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioLance.